Xencor, Novartis deal

Xencor granted Novartis rights to develop bispecific antibodies using Xencor’s technology, including rights outside the U.S. to Xencor’s XmAb14045 and XmAb13676. The companies

Read the full 231 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE